A cohort study of people with type 2 diabetes found that new users of metformin had a lower risk of developing cancer compared to those who had not used the drug. The study, conducted in Tayside, Scotland, used record-linkage databases and followed participants over a period of up to 10 years. Among 4,085 metformin users, 7.3% were diagnosed with cancer, compared to 11.6% of 4,085 comparators who had not used metformin. The median time to cancer diagnosis was 3.5 years for metformin users and 2.6 years for comparators. The unadjusted hazard ratio for cancer was 0.46, and after adjusting for various factors, it was 0.63, indicating a reduced risk of cancer associated with metformin use. The study suggests that metformin may reduce the risk of cancer in people with type 2 diabetes. However, the results are based on observational data, and further research, such as a randomized trial, is needed to confirm these findings. The study also found that metformin users had lower overall and cancer-related mortality compared to non-users. The biological mechanism may involve metformin's activation of AMP-activated protein kinase (AMPK), which can suppress tumor formation and inhibit cell growth. The study highlights the potential of metformin as a cancer preventive agent, although more research is needed to confirm its protective effects.A cohort study of people with type 2 diabetes found that new users of metformin had a lower risk of developing cancer compared to those who had not used the drug. The study, conducted in Tayside, Scotland, used record-linkage databases and followed participants over a period of up to 10 years. Among 4,085 metformin users, 7.3% were diagnosed with cancer, compared to 11.6% of 4,085 comparators who had not used metformin. The median time to cancer diagnosis was 3.5 years for metformin users and 2.6 years for comparators. The unadjusted hazard ratio for cancer was 0.46, and after adjusting for various factors, it was 0.63, indicating a reduced risk of cancer associated with metformin use. The study suggests that metformin may reduce the risk of cancer in people with type 2 diabetes. However, the results are based on observational data, and further research, such as a randomized trial, is needed to confirm these findings. The study also found that metformin users had lower overall and cancer-related mortality compared to non-users. The biological mechanism may involve metformin's activation of AMP-activated protein kinase (AMPK), which can suppress tumor formation and inhibit cell growth. The study highlights the potential of metformin as a cancer preventive agent, although more research is needed to confirm its protective effects.